Eupatilin exerts neuroprotective effects in mice with transient focal cerebral ischemia by reducing microglial activation (original) (raw)
Fig 5
Eupatilin reduces microglial activation in the post-ischemic brain 3 days after tMCAO challenge.
Mice were challenged with tMCAO and eupatilin (Eup, 10 mg/kg, p.o.) was administered immediately after reperfusion. Effects of eupatilin (Eup) on microglial activation and morphological change were assessed in tMCAO-challenged brain 3 days after reperfusion by immunohistochemistry against Iba1. (A) Representative images for Iba1-immunopositive cells in periischemic (‘P’) and ischemic core (‘C’) regions. Diagram boxes in top panels display brain areas where the images in lower panels were acquired. Dashed lines indicate the lesion site. Scale bars, 200 μm (top panels) and 50 μm (middle and bottom panels). (B) Quantification of Iba1-immunopositive cells in both regions. (C) Quantification of morphological changes of Iba1-positive cells in ischemic core region (from ‘ramified’ into ‘amoeboid’ cells) by dividing the number of amoeboid cells with ramified cells. n = 5 per group. *P<0.05 and ***P<0.001 versus vehicle-treated tMCAO (tMCAO+veh).